The General Counsel for MRNA, Lori Henderson has gone ahead and sold around 6,600 shares of the stocks of the company in a 22nd April transaction. The average price per share was $168.26, which brings the total value to a sum of $1,110,516. Currently, the General counsel has ownership of around 7,501 shares of the company which has a total valuation of above $1 million. The documentation for the transaction is located on the official SEC website.
The Quarterly Estimates Of MRNA
The stocks of MRNA traded on Friday at $5.53. The quick ratio for the company has been set at 2.43, with a 2.43 current ratio, along with a 0.04 debt-to-equity ratio. The market cap for the firm has been set at $69.54 billion, with a PE ratio of around -107.18, and a 0.53 PEG ratio. The year low for the company is $45.01, with the year high coming to $189.26. The moving average price of the company over a period of 50 days is $141.27, with the moving average price over 200 days coming to $126.97.
MRNA published its previous quarterly report on the 25th of February. The EPS reported by the company for the quarter was $0.69, which was more than the consensus estimate of $0.25. The revenue generated by the company in this period was $570.80 million, while the consensus estimate was around $279.41 million. The net margin for the company was -242.73%, with the return on its equity at -28.11%.
There have been quite a few research equities that have commented on the stocks of MRNA. Needham & Company LLC has reaffirmed their hold rating in a 16th April research note. Jefferies Financial has also increased the price target of the company from $150 to $180 in a Thursday research report. Piper Sandler has also come up with a rating of overweight along with a price target of $234 in a Wednesday research report. Zacks Investment Research has reduced the price rating of the company from buy to hold with a price target of $170 in a Tuesday research report.
